Partnering for Progress: Industry’s Role in Endocrinology

How the Endocrine Society’s Corporate Liaison Board fosters collaboration, fuels innovation, and advances patient care

The Endocrine Society (the Society) strives to foster an interdisciplinary community of those practicing, researching, and innovating in endocrinology. Industry is an important site of innovation in endocrinology, and the Society’s Corporate Liaison Board (CLB) plays a pivotal role in connecting industry and the global endocrine community.

As the landscapes of science and medicine continue to evolve, these relationships are more important than ever. “The Corporate Liaison Board provides a forum for meaningful engagement between the Society and industry, grounded in shared goals and mutual respect,” says Society CEO Kate Fryer.

Member organizations join the CLB to increase visibility and connect with the world’s largest community of endocrinologists and endocrine researchers, and to foster partnerships on mutually beneficial initiatives in the endocrine space.

The CLB creates a platform for regular and direct communication between Society and industry members. CLB membership delivers organizations meaningful opportunities to build sustained engagement with the endocrine field. Member organizations join the CLB to increase visibility and connect with the world’s largest community of endocrinologists and endocrine researchers, and to foster partnerships on mutually beneficial initiatives in the endocrine space.

Achieving a Common Goal: Advancing Endocrinology

Through the CLB, member organizations engage directly with Society representatives and leadership on a regular basis. These interactions provide CLB members with key insights into emerging challenges in clinical practice, research, and policy developments while also creating space for open dialogue around shared priorities in endocrine health. CLB members have also become key supporters of Society initiatives to address gaps in hormone healthcare. “Our partnership with the Endocrine Society through the Corporate Liaison Board strengthens our ability to engage with society leaders and stay grounded in the real-world needs of patients and providers,” says Sanjay Keswani, MD, Chief Medical Officer, Neurocrine Biosciences. “That connection is essential to advancing innovation in endocrinology and developing therapies that address serious, often underserved conditions.”

According to Robert L. Lash, MD, the Endocrine Society’s chief medical officer, many of the Society’s signature pipeline programs such as the Medical School Education Program, ExCEL, and Endocrine Mentor Day, would not be possible without the support of CLB members. “CLB members also play an invaluable role in our educational programs,” Lash says. “These include longstanding events like the T1D Fellows program at ENDO as well as new programs, such as our inaugural Rare Endocrine Diseases Fellows program that debuted earlier this year.”

From thought leadership to year-round collaboration, these organizations exemplify what is possible when industry and the endocrine community work together toward a shared purpose.

In addition to supporting the continued growth of the endocrine field, CLB members’ partnership with the Society increases educational programming, supports professional development of endocrinologists and researchers, and elevates the conversation around endocrine health and research on the global stage. “The Endocrine Society continues to set the standard as the leader in education and professional support for the endocrinology profession, and [Corcept’s] participation in the CLB has strengthened our ability to contribute meaningfully to the field,” says Rob Adamoski, MBA, Vice President Medical Affairs at Corcept Therapeutics.

The Endocrine Society extends its sincere gratitude to the 23 member organizations which currently comprise the 2026 Corporate Liaison Board, whose ongoing commitment fuels progress across the field. From thought leadership to year-round collaboration, these organizations exemplify what is possible when industry and the endocrine community work together toward a shared purpose.

— Booker is the manager of Grants & Engagement at the Endocrine Society.

The post Partnering for Progress: Industry’s Role in Endocrinology appeared first on Endocrine News.